Formulary Watch |

FDA Approves Heart Failure Therapy that Provides an Alternative to Hospital Treatment

Furoscix can be administered at home with the use of the On-Body Infusor, which delivers furosemide over five hours. It will be launched in the first quarter of 2023.

Insurance Access to Digital Therapeutics Continues to Grow

FDA Uses Real-World Data to Approve Boostrix for Prevention of Infection in Infants

Regulators used a re-analysis of data from an observational case-control study of Tdap vaccine effectiveness to show that Boostrix given in the third-trimester prevented pertussis among infants.

FDA Approves Label Expansion for Oxlumo

This approval for Oxlumo adds lowering plasma oxalate levels for patients with primary hyperoxaluria type 1, a rare and life-threatening metabolic disease.

Capital Blue Cross Teams up with Mark Cuban’s Pharmacy

In 2023, Capital Blue Cross members will be able to use their insurance cards at Mark Cuban Cost Plus Drugs. This is the first time the online pharmacy will accept insurance.

EmpiRx Health Lowers Drug Spend in Mental Health

Eiger Will Not Submit EUA For COVID-19 Treatment

UPDATED: UnitedHealthcare Makes Formulary Changes for Medicare Plans

UnitedHealthcare is moving more drugs to the lower-cost tiers in its Medicare Advantage plans. Other plans will have $0 copays and insulin at a $25 copay.

FDA Accepts BLA for Takhzyro in Young Children with HAE

The FDA is expected to make a decision on approval in this patient population in the first half of 2023.

OIG: One-third of Accelerated Approvals have Delayed Confirmatory Trials

Mark Cuban Pharmacy Adds Products, Lowers Costs on Others

The online pharmacy has added 12 new products and lowered the costs of 39 medications.

U.S. to Buy up to $10.7 Million of Monkeypox Treatment

Cigna to Offer Three Stand-alone Medicare Drug Plans

All plans have $0 copay options for select medications purchased through preferred home delivery.

Label Mix Up Leads to Recall of Clopidogrel and Atenolol

In one lot, a bottle containing clopidogrel was mislabeled as atenolol. This lot was sold to AmerisourceBergen and McKesson.

FDA Approves New Administration Method for Trogarzo in HIV

Trogarzo was approved with a new method of administration designed to make maintenance dosing easier for patients and healthcare providers.

Humana Updates Medicare Pharmacy Benefits

BioMarin Resubmits BLA for Hemophilia A Gene Therapy

Kroger Health to Terminate Express Scripts Agreement

FDA Approves Therapy for Bile Duct Cancer

Taiho’s Lytgobi is approved to treat advanced or metastatic advanced bile duct cancer in patients with FGFR2 gene fusions.

Wellcare Expands Medicare Drug Coverage, Adds Amazon as Preferred Pharmacy

A new formulary design will be offered on the Value Script and Value Plus plans; it will contain medications used to treat diabetes and will cost only $11 per 30-day supply.

FDA Approves Amylyx’s ALS Therapy

FDA Approves Duxipent for Rare Skin Disorder

Dupixent is the first treatment approved to treat prurigo nodularis, a chronic skin disorder characterized by the presence of hard, itchy nodules.

Eugia US Recalls One Lot of Acyclovir

Dark red, brown and black particulates were seen inside of one vial. Acyclovir is used to treat genital herpes and shingles.

IQVIA: Payers Increase Exclusions for Oncology Drugs

FDA Approves Fourth Avastin Biosimilar

Vegzelma is Celltrion’s third oncology biosimilar to be approved by the FDA.

FDA Accepts NDA for Therapy for Rare Immunodeficiency Disease

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, for a decision on leniolisib as a treatment for APDS, a rare primary immunodeficiency.

New Report: Generics, Biosimilars Saved $373 Billion

Optum’s Efforts Combat Opioid Misuse and Abuse

FDA Approves Omlonti for Glaucoma

Omlonti is approved to reduce elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension

First PBM Integrates with Mark Cuban Cost Plus Drug Company

Rightway offers access to generic drugs offered by Cost Plus Drug through its mobile app.